Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Active-Controlled, Safety and Efficacy Study of Oral Baricitinib in Patients from 2 Years to Less Than 18 Years Old with Active Juvenile Idiopathic Arthritis-Associated Uveitis or Chronic Anterior Antinuclear Antibody Positive Uveitis

Next Previous
Trial Profile

An Open-label, Active-Controlled, Safety and Efficacy Study of Oral Baricitinib in Patients from 2 Years to Less Than 18 Years Old with Active Juvenile Idiopathic Arthritis-Associated Uveitis or Chronic Anterior Antinuclear Antibody Positive Uveitis

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Baricitinib (Primary) ; Adalimumab
  • Indications Anterior uveitis; Uveitis
  • Focus Registrational; Therapeutic Use
  • Acronyms JUVE-BRIGHT
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 13 Dec 2024 Planned End Date changed from 21 Jul 2028 to 1 Jul 2028.
  • 15 Jun 2024 Primary endpoint (Percentage of Responders) has not been met, according to results presented at the 25th Annual Congress of the European League Against Rheumatism.
  • 15 Jun 2024 Results (n=29) assessing the efficacy and safety of baricitinib when administered to paediatric patients with active JIA-U or chronic anterior ANA-positive uveitis, who had an inadequate response to MTX or bDMARDs and are receiving topical corticosteroid eye drops at a stable dose, presented at the 25th Annual Congress of the European League Against Rheumatism.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top